Docetaxel followed by gemcitabine and irinotecan in solid tumors

ONCOLOGY

Volumn 15, Issue 1 SUPPL. 1, 2001, Pages

  Rocha Lima, Caio Max S ^a   Urbanic, James J ^a   Sherman, Carol A ^a   Brescia, Frank J ^a   Green, Mark R ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DOCETAXEL; DRUG DERIVATIVE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; PACLITAXEL; TAXOID;

CLINICAL TRIAL; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS; DEOXYCYTIDINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; SURVIVAL RATE; TAXOIDS;

EID: 0035228103     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Gueritte-Voegelein F, Guenard D, Lavelle F, et al: Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34:992-998, 1991.
2. Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 83:288-291, 1991.
3. Lund B, Kristjansen PEG, Hansen HH: Clinical and preclinical activity of 2′,2′-difluorode-oxycytidine (gemcitabine). Cancer Treat Rev 19:45-55, 1993.
4. Plunkett W, Huang P, Searcy CE, et al: Gemcitabine: Preclinical pharmacology and mechanism of action. Semin Oncol 23(suppl 10):3-15, 1996.
5. Kawato Y, Aonuma M, Hirota Y, et al: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191, 1991.
6. Zoli W, Ricotti L, Dal Susino M, et al: Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br J Cancer 81:609-615, 1999.
7. Vanhoefer U, Hilger RA, Harstrick A, et al: Schedule-dependent cytotoxic interactions of Irinotecan (SN-38) and docetaxel in human non-small-cell lung cancer (NSCLC) (abstract 649). Proc Am Assoc Cancer Rev 131, 1999.
8. Okishio K, Kudoh S, Hirata K, et al: Schedule dependent additive effect of docetaxel and irinotecan in vitro (abstract 2252). Proc Jpn J Cancer Res 86:619, 1995.
9. Bahadori HR, Rocha Lima CS, Green MR, et al: Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 19:5423-5428, 1999.
10. Rocha Lima CS, Leong SS, Sherman CA, et al: Phase I study of irinotecan and gemcitabine in patients with solid tumors. Cancer Therapeut 2:58-66, 1999.
11. Rocha Lima CS, Savarese D, Bruckner H, et al: Phase II study of irinotecan and gemcitabine (IrinoGem) in patients with previously untreated advanced and metastatic pancreatic cancer (PC) (abstract 1023). Proc Am Soc Clin Oncol 19:263a, 2000.
12. Eckardt JR, Von Hoff DD: New drugs in clinical development in the United States. Hematol Oncol Clin North Am 8:305-332, 1994.